Should rituximab be used prior to autologous stem-cell transplantation for non-Hodgkin's lymphoma?
José Rodriguez
Correspondence Servicio de Oncologia, Hospital Son Dureta, Andrea Dona 55, Palma Mallorca 07014, Spain
Email jrodriguez@hsd.es
This article has no abstract so we have provided the first paragraph of the full text.
Efficacy of ASCT for patients with NHL depends on the chemosensitivity of disease, amount of residual disease before and after the procedure and potential reintroduction of neoplastic cells within the autologous graft.1 Incorporation of rituximab within the more commonly used salvage regimens has substantially increased both total and complete response rates.2 Randomized studies are ongoing to confirm these preliminary data.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.